Salvage regimens for Hodgkin lymphoma

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 7, 2008, Pages 517-524

  Cashen, Amanda F ^a   Bartlett, Nancy L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autologous stem cell transplantation; Hodgkin lymphoma; Salvage chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MDX 060; MELPHALAN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NAVELBINE; PLATINUM COMPLEX; PREDNISONE; PROCARBAZINE; RITUXIMAB; SGN 30; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOPENIA; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; INFECTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; REVIEW; SALVAGE THERAPY; SECOND CANCER; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; AUTOTRANSPLANTATION; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RECURRENT DISEASE; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; HODGKIN DISEASE; HUMANS; RECURRENCE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 52149098833     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Canellos G, Anderson J, Propert K, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478-1484.
2. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and Increased-Dose BEA-COPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. N Engl J Med. 2003;348:2386-2395.
3. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483-3489.
4. Duggan DB, Petroni GR, Johnson JL, et al. Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin's Disease: Report of an Intergroup Trial. J Clin Oncol. 2003;21:607-614.
5. Josting A, Franklin J, May M, et al. New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin's Lymphoma Registered in the Database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2002;20:221-230.
6. Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 1996;78:1293-1299.
7. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol. 1997;15:528-534.
8. Sureda A, Constant M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625-633.
9. Gutierrez-Delgado F, Holmberg L, Hooper H, et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant. 2003;32:279-285.
10. Sureda A, Arranz R, Iriondo A, et al. Autologous Stem-Cell Transplantation for Hodgkin's Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19:1395-1404.
11. Martin A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol. 2001;113:161-171.
12. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2006;38:211-216.
13. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102:53-59.
14. Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007;109:2481-2489.
15. Chopra R, McMillan A, Linch D, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood. 1993;81:1137-1145.
16. Bierman PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients. Ann Oncol. 1993;4:767-773.
17. Holland DW, Engelhardt BG, Goodman SA, et al. High dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2006;24:7552.
18. Armitage JO, Bierman PJ, Vose JM, et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med. 1991;91:605-611.
19. Reece D, Connors J, Spinelli J, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood. 1994;83:1193-1199.
20. Linch DC, Goldstone AH, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease; results of a BNL1 randomized trial, Lancet. 1993;341:1051-1054.
21. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359:2065-2071.
22. Schmitz N, Haverkamp H, Josting A, et al. Long term follow up in relapsed Hodgkin's disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). J Clin Oncol. 2005;23:6508.
23. Constans M, Sureda A, Terol MJ, et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol. 2003;14:745-751.
24. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96: 1280-1286.
25. Ferme C, Mounier N, Divine M, et al. Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol. 2002;20:467-475.
26. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol. 2004;124:645-652.
27. Metcalfe TL, Gooley TA, Press OW, et al. Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin's Lymphoma. Blood. 2005;106:2081.
28. Salvagno L, Soraru M, Aversa SML, et al. Late relapses in Hodgkin's disease; Outcome of patients relapsing more than twelve months after primary chemotherapy. Ann Oncol. 1993;4:657-662.
29. Viviani S, Santoro A, Negretli E, Bonfante V, Valagussa P, Bonadonna G. Original article: Salvage chemotherapy in Hodgkin's disease: Results in patients relapsing more than twelve months after first complete remission. Ann Oncol. 1990;1:123-127.
30. Kroger, Zeller, Fehse, et al. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br J Haematol. 1998;102:1101-1106.
31. Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell- toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 1995;86:3970-3978.
32. Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol. 1999;10;593-595.
33. Alvarez I, Sureda A, Arranz R, et al. Cisplatin-Based Protocols as Salvage Therapy for Relapsed or Refractory Hodgkin's Lymphoma Patients. Blood. 2005; 106:2676.
34. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/ cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002;13;1628-1635.
35. Smardova L, Engert A, Haverkamp H, et al. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma. 2005;46:1017-1022.
36. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616-623.
37. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma. J Clin Oncol. 1999;17:3776-3785.
38. Jackson G, Angus B, Carey P, et al. High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem tell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy. Leuk Lymphoma. 2000;37:561-570.
39. Proctor SJ, Jackson GH, Lennard A, et al. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Ann Oncol. 2003;14(suppl 1):147-50.
40. Bishton HJ, Lush RJ, Byrne JL, Russell NH, Shaw BE, Haynes AP. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol. 2007;136:752-761.
41. McQuaker IG, Haynes AP, Stainer C, Byrne JL, Russell NH. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Bone Marrow Transplant. 1999;24:715-722.
42. Venkatesh H, Di Bella N, Flynn T, Vellek M, Boehm K, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma. 2004;5: 110-115.
43. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the Treatment of Refractory Hodgkin's Disease: Results of a Multicenter Phase II Study. J Clin Oncol. 2000;18:2615-2619.
44. Zinzani P, Bendandi H, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica. 2000;85:926-929.
45. Peters G, Bergman A, Ruiz van Haperen V, Veerman G, Kuiper C, Braakhuis B. Interaction between ciplatin and gemcitabine in vitro and in vivo. Semin Oncol. 1995;22;72-79.
46. Ng M, Waters J, Cunningham D, et al. Gemcitabine, cisplatin, and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer. 2005;92:1352-1357.
47. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer. 2006;106; 353-360.
48. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol. 1994;5:817-820.
49. Bartlett N, Niedzwiecki D, Johnson J, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007;18:1071-1079.
50. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007;92:35-41.
51. Magagnoli M, Spina M, Balzarotti M, et al. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimens in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007;40:1019-1025.
52. Sohier WD, Wong RKL, Aisenberg AC. Vinblastine in the treatment of advanced Hodgkin's disease. Cancer. 1968;22:467-472.
53. Jones R, Piantadosi S, Mann R, et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1990;8: 527-537.
54. Anderson J, Litzow M, Appelbaum F, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol. 1993;11:2342-2350.
55. Akpek G, Ambinder RF, Piantadosi S, et al. Long-Term Results of Blood and Marrow Transplantation for Hodgkin's Lymphoma. J Clin Oncol. 2001;19: 4314-4321.
56. Gajewski J, Phillips G, Sobocinski K, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol. 1996;14: 572-578.
57. Peniket AJ, Elvira MCRd, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667-678.
58. Milpied N, Fielding A, Pearce R, Ernst P, Goldstone A. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14:1291-1296.
59. Phillips G, Reece D, Barnett M, et al. Allogeneic marrow transplantation for refractory Hodgkin's disease. J Clin Oncol. 1989;7:1039-1045.
60. Robinson SP, Schmitz N, Taghipour G, Sureda A. Reduced Intensity Allogeneic Stem Cell Transplantation for Hodgkin's Disease. Outcome Depends Primarily on Disease Status at the Time of Transplantation. Blood. 2004;104:2322.
61. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365:1934-1941.
62. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005;35:943-951.
63. Burroughs LM, Maris MB, Sandmaier BM, et al. HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). Biol Blood Marrow Transplant. 2004;10(suppl 1):73.
64. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol, Biol Blood Marrow Transplant. 2006;12:172-183.
65. Thomson KJ, Peggs KS, Smith P, et al. Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin's Lymphoma Relapsing Post-Autologous Transplantation. Blood. 2005;106:657.
66. Sureda A, Robinson S, Canals C, et al. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis Front the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455-462.
67. Bartlett NL, Younes A, Catabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111:1848-1854.
68. Leonard JP, Rosenblatt JD, Bartlett NL, et al. Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin's Disease. Blood. 2004;104:2635.
69. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2007;25:2764-2769.
70. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458-1465.
71. Younes A, Forero-Torres A, Bartlett N, et al. A Novel Antibody-Drug Conjugate. SGN-35 (Anti-CD30-Auristatin), Induces Objective Responses in Patients with Relapsed or Refractory Hodgkin Lymphoma: Preliminary Results of a Phase I Tolerability Study. Haematologica. 2007; 92:64.
72. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98:310-314.
73. Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008;112:831-836.
74. Friedberg JW, Leonard JP, Younes A, et al. Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL. Blood. 2005;106:2435.
75. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma. J Clin Oncol. 2005;23:4390-4398.
76. Zheng B, Georgakis GV, Li Y, et al. Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-kappa B Mutations or Activation of the CD30, CD40, and RANK Receptors. Clin Cancer Res. 2004;10:3207-3215.
77. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood. 2006;107: 1731a-1732.
78. Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. Leuk Lymphoma. 2007;48:1313-1319.
79. Younes A, Fanale M, Pro B, et al. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol. 2007;25:8000.
80. Kutuvilla J, Song K, Mollee P, et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology. 2006; 11:25-29.